r/biotech
“Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.
- upvotes
- 300
- comments
- 59
Extracted from these lines
Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.
From the post
[comment u/Sorry_Clerk2646] We could all be as “unfortunate” as to make 73 billion USD in cumulative revenue while curing millions of people from an awful disease
[comment u/LeoKitCat] Sales “languish” at $4 billion a year? What the hell? It’s still a blockbuster drug even with today’s sales!